BioSpace News Archive

CARB-X is awarding Pattern Bioscience (formerly operating as Klaris Diagnostics), based in Austin, Texas, US, up to US$6.8 million in non-dilutive funding to develop a rapid identification and antimicrobial susceptibility test (ID/AST) to diagnose drug resistant infections quickly, and provide health professionals with vital information about which pathogen is causing the infection and which antibiotic is most likely to cure the infection.

The Alpha Genesis Primate Research Center is utilizing its considerable resources to develop a much-needed vaccine to battle what looks to be an emerging pandemic.

Health Canada is warning Canadians that skin lightening health products — such as creams or gels — that are not authorized for sale in Canada may pose serious health risks.

Alydia Health, a clinical-stage medical device company dedicated to making childbirth safer for all mothers, today announced that the company has completed enrollment in the pivotal PEARLE IDE Study

Utilizing NowPow’s platform, community-based organizations will connect patients to available services that are traditionally fragmented and difficult to navigate

Dave Schwartzman brings more than twenty-five years of industry experience to new role for Demers and Crestline brands

On January 2, 2020, Health Share of Oregon learned that the personal information of its members was located on a laptop stolen from GridWorks IC, Health Share’s contracted non-emergent medical transportation vendor.

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 161,000 ordinary shares of Nabriva Therapeutics as inducements to 5 newly-hired employees.

Centene Corporation announced that it has priced its offering of $2,000,000,000 aggregate principal amount of 3.375% of new senior notes due 2030.